Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 50

1.

The localization of pre mRNA splicing factor PRPF38B is a novel prognostic biomarker that may predict survival benefit of trastuzumab in patients with breast cancer overexpressing HER2.

Abdel-Fatah TMA, Rees RC, Pockley AG, Moseley P, Ball GR, Chan SYT, Ellis IO, Miles AK.

Oncotarget. 2017 Nov 18;8(68):112245-112257. doi: 10.18632/oncotarget.22496. eCollection 2017 Dec 22.

2.

A novel spontaneous model of epithelial-mesenchymal transition (EMT) using a primary prostate cancer derived cell line demonstrating distinct stem-like characteristics.

Harner-Foreman N, Vadakekolathu J, Laversin SA, Mathieu MG, Reeder S, Pockley AG, Rees RC, Boocock DJ.

Sci Rep. 2017 Jan 17;7:40633. doi: 10.1038/srep40633.

3.

SPAG5 as a prognostic biomarker and chemotherapy sensitivity predictor in breast cancer: a retrospective, integrated genomic, transcriptomic, and protein analysis.

Abdel-Fatah TMA, Agarwal D, Liu DX, Russell R, Rueda OM, Liu K, Xu B, Moseley PM, Green AR, Pockley AG, Rees RC, Caldas C, Ellis IO, Ball GR, Chan SYT.

Lancet Oncol. 2016 Jul;17(7):1004-1018. doi: 10.1016/S1470-2045(16)00174-1. Epub 2016 Jun 14.

PMID:
27312051
4.

Prediction of Pathological Stage in Patients with Prostate Cancer: A Neuro-Fuzzy Model.

Cosma G, Acampora G, Brown D, Rees RC, Khan M, Pockley AG.

PLoS One. 2016 Jun 3;11(6):e0155856. doi: 10.1371/journal.pone.0155856. eCollection 2016.

5.

HAGE in Triple-Negative Breast Cancer Is a Novel Prognostic, Predictive, and Actionable Biomarker: A Transcriptomic and Protein Expression Analysis.

Abdel-Fatah TM, McArdle SE, Agarwal D, Moseley PM, Green AR, Ball GR, Pockley AG, Ellis IO, Rees RC, Chan SY.

Clin Cancer Res. 2016 Feb 15;22(4):905-14. doi: 10.1158/1078-0432.CCR-15-0610. Epub 2015 Aug 3.

6.

Data Mining of Gene Arrays for Biomarkers of Survival in Ovarian Cancer.

Coveney C, Boocock DJ, Rees RC, Deen S, Ball GR.

Microarrays (Basel). 2015 Jul 17;4(3):324-38. doi: 10.3390/microarrays4030324.

7.

Controlling the dynamics of cell transition in heterogeneous cultures using surface chemistry.

Hickman GJ, Rees RC, Boocock DJ, Pockley AG, Perry CC.

Adv Healthc Mater. 2015 Mar 11;4(4):593-601. doi: 10.1002/adhm.201400525. Epub 2014 Nov 13.

PMID:
25393206
8.

Prostate cancer: Important steps and considerations in the design of therapeutic vaccines.

McArdle SE, Pockley AG, Gibson GR, Rees RC.

Oncoimmunology. 2014 Feb 14;3:e28049. eCollection 2014.

9.

Novel prostate acid phosphatase-based peptide vaccination strategy induces antigen-specific T-cell responses and limits tumour growth in mice.

Saif JM, Vadakekolathu J, Rane SS, McDonald D, Ahmad M, Mathieu M, Pockley AG, Durrant L, Metheringham R, Rees RC, McArdle SE.

Eur J Immunol. 2014 Apr;44(4):994-1004. doi: 10.1002/eji.201343863. Epub 2014 Mar 7.

10.

Identification of novel breast cancer-associated transcripts by UniGene database mining and gene expression analysis in normal and malignant cells.

Laversin SA, Phatak VM, Powe DG, Li G, Miles AK, Hughes DC, Ball GR, Ellis IO, Gritzapis AD, Missitzis I, McArdle SE, Rees RC.

Genes Chromosomes Cancer. 2013 Mar;52(3):316-29. doi: 10.1002/gcc.22031. Epub 2012 Dec 8.

PMID:
23225347
11.

The helicase HAGE expressed by malignant melanoma-initiating cells is required for tumor cell proliferation in vivo.

Linley AJ, Mathieu MG, Miles AK, Rees RC, McArdle SE, Regad T.

J Biol Chem. 2012 Apr 20;287(17):13633-43. doi: 10.1074/jbc.M111.308973. Epub 2012 Mar 5.

12.

Expression of the tumour antigen T21 is up-regulated in prostate cancer and is associated with tumour stage.

Miles AK, Rogers A, McCulloch T, Hodi Z, McArdle S, Bishop M, Rees RC.

BJU Int. 2012 Mar;109(5):796-805. doi: 10.1111/j.1464-410X.2011.10407.x. Epub 2011 Aug 18.

13.

Immunotherapy of prostate cancer: should we be targeting stem cells and EMT?

Dunning NL, Laversin SA, Miles AK, Rees RC.

Cancer Immunol Immunother. 2011 Aug;60(8):1181-93. doi: 10.1007/s00262-011-1065-8. Epub 2011 Jun 19. Review.

PMID:
21688178
14.

Tumour-associated antigens: considerations for their use in tumour immunotherapy.

Linley AJ, Ahmad M, Rees RC.

Int J Hematol. 2011 Mar;93(3):263-273. doi: 10.1007/s12185-011-0783-1. Epub 2011 Mar 1. Review.

PMID:
21360066
15.

HAGE, a cancer/testis antigen expressed at the protein level in a variety of cancers.

Mathieu MG, Linley AJ, Reeder SP, Badoual C, Tartour E, Rees RC, McArdle SE.

Cancer Immun. 2010 Jan 11;10:2.

16.

Tumor immunology: new perspectives.

McArdle SE, Rees RC.

Cancer Res. 2009 Sep 15;69(18):7157-9. doi: 10.1158/0008-5472.CAN-09-0631. Epub 2009 Sep 8.

17.

Estimation of peptide concentration by a modified bicinchoninic acid assay.

Kapoor KN, Barry DT, Rees RC, Dodi IA, McArdle SE, Creaser CS, Bonner PL.

Anal Biochem. 2009 Oct 1;393(1):138-40. doi: 10.1016/j.ab.2009.06.016. Epub 2009 Jun 17.

PMID:
19539599
18.

Artificial exosomes as tools for basic and clinical immunology.

De La Peña H, Madrigal JA, Rusakiewicz S, Bencsik M, Cave GW, Selman A, Rees RC, Travers PJ, Dodi IA.

J Immunol Methods. 2009 May 31;344(2):121-32. doi: 10.1016/j.jim.2009.03.011. Epub 2009 Apr 1.

PMID:
19345222
19.

Tumour antigen-targeted immunotherapy for chronic myeloid leukaemia: is it still viable?

Riley CL, Mathieu MG, Clark RE, McArdle SE, Rees RC.

Cancer Immunol Immunother. 2009 Sep;58(9):1489-99. doi: 10.1007/s00262-009-0675-x. Epub 2009 Mar 4. Review.

PMID:
19259670
20.

Quantitative RT-PCR analysis of estrogen receptor gene expression in laser microdissected prostate cancer tissue.

Walton TJ, Li G, McCulloch TA, Seth R, Powe DG, Bishop MC, Rees RC.

Prostate. 2009 Jun 1;69(8):810-9. doi: 10.1002/pros.20929.

PMID:
19189301

Supplemental Content

Loading ...
Support Center